Stick With Traditional Opioid Formulations for Most Patients

May 2014

The Zohydro controversy will lead to more interest in "abuse-deterrent" opioid formulations.

Zohydro is the new long-acting hydrocodone for chronic, severe pain. It's controversial because it's NOT an abuse-deterrent formulation...despite concerns about its abuse potential.

Abuse-deterrent formulations aren't required by FDA...but are being promoted in an effort to reduce prescription opioid abuse.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology Avoid the New Anticoagulants in Patients With Mechanical Valves
Testosterone Reserve "Low T" Treatment for Symptomatic Men With Repeatedly Low Levels
Alzheimer's Disease Re-Evaluate Whether Namenda Is Helping Your Alzheimer's Patients
Cardiology Use a High-Dose Statin for Most Post-ACS Patients
Respiratory & Allergy Teach Patients How to Use Spacers with Metered Dose Inhalers
Neurology & Pain Stick With Traditional Opioid Formulations for Most Patients
Dermatology Recommend OTC Butenafine or Terbinafine First for Tinea Infections
Diabetes Be Aware of Meds That Increase Diabetes Risk
Geriatrics Look for Alternatives to High-Risk Meds in Elderly Patients
Women's Health Use COMBINED Hormonal Contraceptives for Most Women with PCOS
Supplements Advise Most Patients They Don't Need a Multivitamin
Cardiology Ensure MI Patients Get the Right Discharge Meds
OTC Products Be Aware that Mucinex Allergy does NOT Contain Guaifenesin

Stick With Traditional Opioid Formulations for Most Patients

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents